Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALDX 
Aldeyra The (ALDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ALDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.15% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 351.27M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 7 | Beta 0.75 | 52 Weeks Range 1.14 - 7.20 | Updated Date 08/28/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date 2025-08-27 | When - | Estimate -0.2433 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.58% | Return on Equity (TTM) -65.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 285503061 | Price to Sales(TTM) - |
Enterprise Value 285503061 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.5 | Shares Outstanding 60045500 | Shares Floating 48481286 |
Shares Outstanding 60045500 | Shares Floating 48481286 | ||
Percent Insiders 3.1 | Percent Institutions 57.58 |
Upturn AI SWOT
Aldeyra The
Company Overview
History and Background
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for immune-mediated diseases. Founded in 2004, it has evolved through clinical trials and strategic partnerships to advance its product pipeline.
Core Business Areas
- Ophthalmology: Development of therapies for ocular diseases, including allergic conjunctivitis, dry eye disease, and other inflammatory eye conditions.
- Systemic Immunometabolic Diseases: Researching and developing treatments for systemic immune and metabolic disorders.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, clinical research, and business management. Organizational structure includes research and development, clinical operations, and commercial strategy departments.
Top Products and Market Share
Key Offerings
- Reproxalap: Reproxalap is Aldeyra's lead investigational new drug candidate for the treatment of dry eye disease (DED) and allergic conjunctivitis (AC). While Reproxalap is not yet approved, its potential market includes millions of DED and AC sufferers. Major competitors in the DED market include Novartis (Xiidra), AbbVie (Restasis), and Sun Pharma (Cequa). The AC market has numerous competitors including generic and branded antihistamines and mast cell stabilizers. Market share data is currently projected pending approval.
- ADX-2191: ADX-2191 is an intravitreal formulation of methotrexate, is being developed for the prevention of proliferative vitreoretinopathy (PVR), a serious sight-threatening condition. Competitors for PVR prevention are limited.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. There is strong competition in the ophthalmology therapeutic area.
Positioning
Aldeyra is positioned as an innovator in the development of novel therapies for immune-mediated diseases, focusing on addressing unmet medical needs in specific patient populations. Their competitive advantage lies in their NRF2 modulation technology.
Total Addressable Market (TAM)
The total addressable market for Aldeyra's lead product candidates in ophthalmology is estimated to be several billion dollars. Aldeyra is targeting specific segments within these markets with its novel therapies.
Upturn SWOT Analysis
Strengths
- Novel NRF2 modulation technology
- Strong intellectual property portfolio
- Experienced management team
- Targeting unmet medical needs
Weaknesses
- Reliance on successful clinical trials and regulatory approvals
- Limited commercial infrastructure
- Cash burn rate
- Dependence on external funding
Opportunities
- Potential for strategic partnerships and collaborations
- Expansion into new therapeutic areas
- Successful commercialization of lead product candidates
- Favorable regulatory environment
Threats
- Competition from larger pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- Novartis (NVS)
- AbbVie (ABBV)
- Sun Pharma (SUNPHARMA.NS)
Competitive Landscape
Aldeyra faces competition from established pharmaceutical companies with significant resources. Aldeyra's advantages lie in their innovative approach and targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Aldeyra's historical growth has been characterized by progress in clinical trials and regulatory submissions.
Future Projections: Future growth is heavily dependent on the successful approval and commercialization of its lead product candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing reproxalap through regulatory review, expanding clinical trials, and exploring strategic partnerships.
Summary
Aldeyra is a clinical-stage biotech company with promising technology targeting unmet needs, especially in ophthalmology. The company is currently pre-revenue and heavily reliant on positive clinical trial outcomes and regulatory approvals. Financial stability depends on future funding and the successful commercialization of its lead products. The company must navigate a competitive market and carefully manage its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Aldeyra Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated based on available sources and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aldeyra The
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. Todd C. Brady M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.aldeyra.com |
Full time employees 8 | Website https://www.aldeyra.com | ||
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.